Reduced Antimicrobial Resistance Gene Diversity After REBYOTA® in rCDI Prevention

Overview

This post hoc analysis of the PUNCH CD3 trial demonstrated that fecal microbiota, live-jslm (REBYOTA®) administration significantly reduced the richness of antimicrobial resistance genes (ARGs) in patients treated for recurrent Clostridioides difficile infection (rCDI). The reduction in ARG diversity was evident within one week and sustained for at least six months compared to placebo.

Background

The human gut microbiome plays a critical role in maintaining colonization resistance against pathogens. Disruption of this microbiome, often due to antibiotic use, can lead to colonization by opportunistic bacteria harboring antimicrobial resistance genes, increasing infection risk. Recurrent Clostridioides difficile infection (rCDI) is a common complication following antibiotic treatment, with high rates of recurrence. Microbiota-based therapies like REBYOTA® aim to restore microbiome diversity and colonization resistance to prevent rCDI and potentially reduce antimicrobial resistance gene carriage.

Data Highlights

Key Findings

• Participants with rCDI had higher baseline antibiotic resistance gene richness compared to healthy controls.
• REBYOTA® responders showed significantly reduced ARG richness at multiple classification levels compared to placebo responders.
• Reduction in ARG richness was observed as early as one week after treatment and persisted for at least six months.
• REBYOTA® responders exhibited decreased richness of ARGs associated with high-risk bacterial public health threats.
• Microbiota restoration via REBYOTA® may reduce the genomic potential for colonization by antimicrobial-resistant organisms.

Clinical Implications

Administration of REBYOTA® not only prevents recurrent CDI but also reduces the diversity of antimicrobial resistance genes in the gut microbiome, potentially lowering the risk of subsequent infections by resistant organisms. This supports the use of microbiota-based therapies as a strategy to restore colonization resistance and combat antimicrobial resistance in clinical practice.

Conclusion

REBYOTA® effectively reduces antimicrobial resistance gene richness in patients treated for rCDI, suggesting a dual benefit of preventing infection recurrence and mitigating antimicrobial resistance gene carriage. These findings highlight the therapeutic potential of microbiota restoration in managing antimicrobial resistance.

References

1. PUNCH CD3 Study (NCT03244644) -- REBYOTA® for Prevention of Recurrent Clostridioides difficile Infection